Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 211 participants.

Also called NCT03386539

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 211 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03386539
Main results
  • Everolimus and Low-Dose Tacrolimus After Heart Transplant in Children: A Randomized Clinical Trial JAMA, 2025-10-21 DOI, PubMed 40960806, PMC12444652 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03386539. Randomized; single masking; primary purpose treatment. Start 2018-01-29 (actual); primary completion 2023-04-17 (actual). Results posted on 2026-07-31.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
Acronym
TEAMMATE
Condition
Pediatric Heart Transplantation
Condition
Immunosuppression
Condition
Chronic Kidney Diseases
Condition
Cardiac Allograft Vasculopathy
Condition
Heart Transplant Failure and Rejection
Condition
Post-transplant Lymphoproliferative Disorder
Condition
Heart Transplant Infection
Intervention (Drug)
Everolimus
Intervention (Drug)
Tacrolimus
Intervention (Drug)
Mycophenolate Mofetil
Lead sponsor
Boston Children's Hospital (class: other)
Collaborator
Stanford University (class: other)
Collaborator
United States Department of Defense (class: US federal agency)

Record details

Record id
cardio:ct-nct03386539
Content hash
38efecc9b57fa942cd90d44e1ea4054c4eea55f819f5ad654d69730d484f3114